Page, David B. http://orcid.org/0000-0001-9264-4628
Beal, Kathryn
Linch, Stefanie N. http://orcid.org/0000-0002-9789-4113
Spinelli, Kateri J.
Rodine, Micaela
Halpenny, Darragh
Modi, Shanu
Patil, Sujata
Young, Robert J.
Kaley, Thomas
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Redmond, David
Wong, Phillip http://orcid.org/0000-0002-6360-849X
Barker, Christopher A.
Diab, Adi
Norton, Larry http://orcid.org/0000-0003-3701-9250
McArthur, Heather L. http://orcid.org/0000-0002-0201-3871
Funding for this research was provided by:
Breast Cancer Research Foundation
Terri Brodeur Breast Cancer Foundation
Article History
Received: 14 April 2021
Accepted: 28 February 2022
First Online: 19 April 2022
Competing interests
: D.B.P. has served on the advisory board for Merck, Syndax, Peregrine, Bristol-Myers Squibb, Puma, and Nanostring; has received research support from Bristol-Myers Squibb, Merck, and Brooklyn ImmunoTherapeutics; and has served on the speaker’s bureau for Genentech and Novartis. K.B., K.J.S., M.R., D.H., S.P., T.K., D.R., and C.A.B. have no disclosures. S.N.L. has received patent royalties from Galectin Therapeutics. R.J.Y. has consulted for Agios, Puma, ICON plc and NordicNeuroLab; has received research support from Agios. S.M. has research funding from Genentech, Daiichi Sankyo, Novartis, AstraZeneca, and Seattle Genetics; she has received speaking fees from Genentech, Daiichi Sankyo, AstraZeneca, and Seattle Genetics; she has consulted for Genentech, Daiichi Sankyo, AstraZeneca, Macrogenics, and Seattle Genetics. T.M. is a cofounder and holds an equity in IMVAQ Therapeutics. He is a consultant of Immunos Therapeutics and Pfizer. He has research support from Bristol-Myers Squibb; Surface Oncology; Kyn Therapeutics; Infinity Pharmaceuticals, Inc.; Peregrine Pharmaceuticals, Inc.; Adaptive Biotechnologies; Leap Therapeutics, Inc.; and Aprea. He has patents on applications related to work on oncolytic viral therapy, alpha virus-based vaccine, neo antigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. P.W. has consulted for Sellas Life Sciences and Leap Therapeutics. A.D. has consultaed for Bristol-Myers Squibb, NEKTAR therapeutics, Pfizer, and Apexigen and has received research support from Bristol-Myers Squibb, Nektar therapeutics, Idera, and Merck. H.L.M. has consulted for Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi Sankyo, Seattle Genetics, AstraZeneca and TapImmune; and has received research support from Bristol-Myers Squibb; MedImmune, LLC/AstraZeneca; BTG; and Merck.